One Nucleus Genesis Digital 2020 – Key takeaways from our cell and gene therapy panel session
8+2+1 plus what? How UK data and market exclusivity rights will be affected from 1 January 2021
by Alison Dennis and Dr Paul England
Biologics and biosimilars litigation update
by Matthew Royle, Ph.D. and Dr. Nora E. Wessendorf, LL.M. (Washington)
SPC for ezetimibe/simvastatin considered invalid in preliminary relief proceedings
Targeted treatments – Part 3: the power of orphan drug protection
German Federal Court of Justice invalidates Truvada SPC
Targeted treatments – Part 1: Targeted treatments: patents for particular populations
Adrian Toutoungi, Josef Fuss and Matt Caskie discuss how biotech has managed its finances during the pandemic
by Adrian Toutoungi and Josef Fuss
Biologics and biosimilars litigation update
